HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds

Area of Science:

• Virology
• Molecular Biology
• Drug Discovery

Background:

• HIV envelope glycoprotein gp41 is essential for viral and target cell membrane fusion.
• gp41 undergoes conformational changes, forming N-helix and six-helix bundles during fusion.
• Peptides targeting gp41's N-heptad repeats (NHRs) and C-heptad repeats (CHRs) inhibit HIV fusion.

Purpose of the Study:

• To review the development of anti-HIV agents targeting gp41.
• To explore the transition from polypeptide-based inhibitors to small-molecule compounds.
• To highlight strategies for blocking HIV-mediated membrane fusion.

Main Methods:

• Analysis of existing research on gp41 inhibitors, including peptides like T-20.
• Review of efforts to develop alternative peptides and proteins with improved properties.
• Examination of the development of small-molecule inhibitors targeting gp41 NHR.

Main Results:

• Peptides derived from gp41 NHR and CHR demonstrate potent HIV fusion inhibitory activity.
• The peptide T-20 was the first successful HIV entry inhibitor but has limitations.
• Small molecules targeting gp41 NHR offer a promising approach to inhibit viral entry.

Conclusions:

• Developing small-molecule inhibitors targeting gp41 NHR is a key strategy against HIV.
• Blocking NHR homotrimerization and six-helix bundle formation inhibits viral fusion.
• Continued research aims for improved bioavailability and reduced production costs of anti-HIV agents.